Corteva, Inc. · NYSE:CTVA

Corteva — Q3 2026 Earnings Presentation

26 slides from Corteva's earnings presentation, Nov 12, 2026

  1. Slide 1: Earnings Call 3Q 2026

    Earnings Call 3Q 2026 NOVEMBER 12, 2026

  2. Slide 2: Safe Harbor Regarding Forward-Looking Statements

    Safe Harbor Regarding Forward-Looking Statements Forward-looking Statements This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, whi

  3. Slide 3: Information Regarding Non-GAAP Financial Measures

    Information Regarding Non-GAAP Financial Measures Regulation G (non-GAAP Financial Measures) This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), adj

  4. Slide 4: CEO Messages

    CEO Messages 1 2 3 Strategy Challenging Market Full Year In Action Environment Expectations2 • Broad-based volume • Resilient on-farm demand for • Full Year Adj. Pro Forma growth in the quarter innovation tempered by Op. EBITDA1 guide of $1.1B across all regions, except delayed purchasing, to $1.125

  5. Slide 5: Our View of the Market

    5 Our View of the Market Market demand Applications remain strong as growers focus on maximizing yield while balancing investment decisions to manage costs Farmer economics Elevated input costs pressure profitability of growers, notably in Brazil given currency and interest rates Channel inventory C

  6. Slide 6: 3Q / YTD 2026 Adjusted Pro Forma Results

    3Q / YTD 2026 Adjusted Pro Forma Results YTD HIGHLIGHTS: Metric 3Q 20261 YTD 20261 Sales growth in NA4, APAC and EMEA4 Net $1.6B $5.4B Sales (9)% (1)% New product growth in all regions, led by Arylex® and Pyraxalt® Organic $1.6B $5.2B Sales3 Pricing headwinds largely concentrated in (9)% (4)% U.S. a

  7. Slide 7: 3Q 2026 Regional Net Sales Performance

    3Q 2026 Regional Net Sales Performance GLOBAL NET SALES NORTH AMERICA 2 Reported • Volume driven by early demand for 3Q 2025 3Q 2026 differentiated products Volume Price/Mix Currency Portfolio 7% Net Sales ($M) Net Sales ($M) $1.74B • Acetochlor drove year-over-year price Organic(1) $537 $574 19% (1

  8. Slide 8: 3Q 2026 Operating EBITDA

    3Q 2026 Adjusted Pro Forma Operating EBITDA1 3Q 2026 Bridge KEY DRIVERS ($ in millions) New products volume growth of 20% across all regions, driven by Arylex® $268 ($119) $6 $222 Volume growth in NA2, EMEA2 and APAC offset by $67 LATAM market challenges ~90% of price impact concentrated in U.S. ace

  9. Slide 9: FY 2026 Guidance

    FY 2026 Guidance1 Adjusted Pro Forma Adjusted Pro Forma Adjusted Pro Forma Operating EBITDA2 Operating EBITDA Operating EPS2 Guidance Margin2 $1.1 – $1.125B $0.76 – $0.80 (12)% at mid-point ~15% +3% at mid-point Softer than anticipated market conditions in Brazil, Key Drivers Lower price and driven

  10. Slide 10: Key Takeaways

    Key Takeaways Focused innovation driving strong new product growth Navigating dynamic 1 market environment While most markets performed in line with expectations, in while remaining Brazil, conditions were materially more challenging than focused on our 2 expected strategic priorities for long-term

  11. Slide 11: Appendix

    Appendix Q3 2026 EARNINGS 11

  12. Slide 12: 3Q 2026 Performance

    3Q 2026 Adjusted Pro Forma Performance ($ in millions) 3Q 2026 vPY 3Q 2026 Revenue by Product Line Net Sales $1,591 (9)% Biologicals Other3 Organic2 Sales Growth (9)% (22)% reported growth Adjusted Pro Forma Operating $222 (17)% (24)% organic2 growth EBITDA1 Adjusted Pro Forma Operating 14% (140) bp

  13. Slide 13: YTD 2026 Regional Net Sales Performance

    YTD 2026 Regional Net Sales Performance GLOBAL NET SALES NORTH AMERICA 2 • Volume growth across most Reported portfolios YTD 2025 YTD 2026 Volume Price/Mix Currency Portfolio Flat Net Sales ($M) Net Sales ($M) • Price declines mostly driven by $5.42B acetochlor and insecticides $5.36B Organic(1) $1,

  14. Slide 14: YTD 2026 Performance

    YTD 2026 Adjusted Pro Forma Performance ($ in millions) YTD 2026 vPY YTD 2026 Revenue by Product Line Net Sales $5,357 (1)% Organic2 Sales Growth (4)% Other3 Biologicals Adjusted Pro Forma Operating $943 Flat (17)% reported growth EBITDA1 (22)% organic2 growth Adjusted Pro Forma Operating 17.6% +30

  15. Slide 15: YTD 2026 Adj. Pro Forma Operating EBITDA

    YTD 2026 Adj. Pro Forma Operating EBITDA1 YTD 2026 Bridge KEY DRIVERS New products volume growth of 14% across all ($ in millions) regions, driven by Arylex®, Pyraxalt® and Rinskor® $937 ($236) $85 $943 Volume growth in NA2, EMEA2 and APAC partially offset by LATAM market challenges $130 ~70% of pri

  16. Slide 16: 3Q 2026 Operating EPS Variance

    3Q 2026 Adjusted Pro Forma Operating EPS1 Variance Operating EPS1 ($) $0.14 ($0.12) $0.01 ($0.02) $0.07 ($0.02) $0.06 1 2 3 4 5 3Q 2025 Price Costs Currency Exchange Gain Tax rate / Other 3Q 2026 Acetochlor and Brazil Lower input costs Currency tailwind / Loss (EGL) Lower tax benefit account for alm

  17. Slide 17: FY 2026 Modeling Guidance – Operating Earnings Per Share

    FY 2026 Modeling Guidance – Adjusted Pro Forma Operating Earnings Per Share1 ($ in millions, except where noted) Guidance Depreciation and Post-Merge Amortization ~(340) Net Interest (Expense) Income (25 – 30) Base Income Tax Rate1 16% – 18% Exchange Losses – net, after tax (75 – 85) Net Income – No

  18. Slide 18: Kinrayza active: differentiated performance with broad global potential

    Kinrayza active: differentiated performance with broad global potential Next-generation control of damaging sap-feeding pests, launching by end of decade1 ~$2.5B5 sap-feeding insecticide market opportunity 40+ countries6 across planned global footprint 70+ crops7 with potential applications ~15M8 po

  19. Slide 19: Trademark notices

    ® Trademark of Corteva Agriscience and its affiliated companies. Always read and follow label directions. © 2026 Corteva.​ Bexfond® biological fungicide is not for sale or use in all states. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in you

  20. Slide 20: Thank you.

    Thank you. Q3 2026 EARNINGS

  21. Slide 21: Non-GAAP Calculation of New Corteva Operating EBITDA

    New Corteva Non-GAAP Calculation of New Corteva Adjusted Pro Forma Operating EBITDA Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 As As As As $ In millions Reported Margin % Reported Margin % Reported Margin % Reported Margin % Pro forma income (loss) from cont

  22. Slide 22: New Corteva Pro Forma Significant Items

    New Corteva Pro Forma Significant Items New Corteva significant items (Pre-tax) Three Months Ended Nine Months Ended September 30, September 30, In millions 2026 2025 2026 2025 Restructuring and asset related charges - net $ (22) $ (30) $ (130) $ (128) Litigation settlement 1 — (120) — Gain (loss) o

  23. Slide 23: Price, Volume, Currency Analysis Region (Q3)

    New Corteva Price, Volume, Currency Analysis Region Q3 2026 vs. Q3 2025 Percent Change Due To: Net Sales Change (GAAP) Organic Change (Non-GAAP) 2 Price & Portfolio / $ (millions) % $ (millions) % Product Mix Volume Currency Other North America 1 $ 37 7%$ 38 7% (12)% 19 % —% —% EMEA 1 26 12 % 29 14

  24. Slide 24: Price, Volume, Currency Analysis Region (Nine Months)

    New Corteva Price, Volume, Currency Analysis Region Nine Months 2026 vs. Nine Months 2025 Percent Change Due To: Net Sales Change (GAAP) Organic Change (Non-GAAP) 2 Price & Portfolio / $ (millions) % $ (millions) % Product Mix Volume Currency Other North America 1 $ 5 —%$ (2) —% (4)% 4% —% —% EMEA 1

  25. Slide 25: Non-GAAP Calculation of Operating EPS

    New Corteva Non-GAAP Calculation of Adjusted Pro Forma Operating EPS Three Months Ended September 30, 2026 2025 2026 2025 $ (millions) $ (millions) EPS (diluted) EPS (diluted) Pro forma net income (loss) attributable to New Corteva (GAAP) $ (56) $ 58 $ (0.08) $ 0.09 Less: Non-operating benefits (cos

  26. Slide 26: Non-GAAP Calculation of Effective Income Tax Rate

    New Corteva Non-GAAP Calculation of Adjusted Pro Forma Effective Income Tax Rate Three Months Ended Nine Months Ended September 30, September 30, $ In millions 2026 2025 2026 2025 Pro forma income (loss) from continuing operations before income taxes (GAAP) $ 63 $ 97 $ 356 $ 500 Add: Significant ite

Corteva — Q3 2026 Earnings Presentation on 6ix